You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEtomidate
Accession NumberDB00292  (APRD00965)
TypeSmall Molecule
GroupsApproved
DescriptionImidazole derivative anesthetic and hypnotic with little effect on blood gases, ventilation, or the cardiovascular system. It has been proposed as an induction anesthetic. [PubChem]
Structure
Thumb
Synonyms
(+)-Ethyl 1-(alpha-methylbenzyl)imidazole-5-carboxylate
(+)-ethyl 1-(α-methylbenzyl)imidazole-5-carboxylate
(+)-etomidate
(R)-(+)-1-(alpha-Methylbenzyl)imidazole-5-carboxylic acid ethyl ester
(R)-1-(1-phenylethyl)-1H-imidazole-5-carboxylic acid ethyl ester
3-((R)-1-Phenyl-ethyl)-3H-imidazole-4-carboxylic acid ethyl ester
Etomidate
Etomidato
Etomidatum
R-(+)-Ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AmidateInjection, solution2 mg/mLIntravenousGENERAL INJECTABLES AND VACCINES, INC.2010-03-10Not applicableUs
AmidateInjection, solution2 mg/mLIntravenousHospira, Inc.1982-09-07Not applicableUs
AmidateInjection, solution2 mg/mLIntravenousGeneral Injectables & Vaccines, Inc2010-08-01Not applicableUs
AmidateInjection, solution2 mg/mLIntravenousHospira, Inc.1982-09-07Not applicableUs
AmidateInjection, solution2 mg/mLIntravenousHospira, Inc.1982-09-07Not applicableUs
AmidateInjection, solution2 mg/mLIntravenousHospira, Inc.1982-09-07Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
EtomidateInjection, solution2 mg/mLIntravenousMylan Institutional LLC2012-02-03Not applicableUs
EtomidateInjection2 mg/mLIntravenousPfizer Laboratories Div Pfizer Inc.2012-02-03Not applicableUs
EtomidateInjection2 mg/mLIntravenousWest Ward Pharmaceuticals Corp2016-02-25Not applicableUs
EtomidateInjection, solution2 mg/mLIntravenousPharma Force, Inc.2010-06-082016-10-13Us
EtomidateInjection, solution2 mg/mLIntravenousMylan Institutional LLC2012-02-03Not applicableUs
EtomidateInjection2 mg/mLIntravenousHeritage Pharmaceuticals Inc.2012-09-13Not applicableUs
EtomidateInjection, solution2 mg/mLIntravenousAmerican Regent, Inc.2010-06-30Not applicableUs
EtomidateInjection, solution2 mg/mLIntravenousCadila Healthcare Limited2015-04-03Not applicableUs
EtomidateInjection, solution2 mg/mLIntravenousZydus Pharmaceuticals (USA) Inc.2015-04-03Not applicableUs
EtomidateInjection2 mg/mLIntravenousHeritage Pharmaceuticals Inc.2012-09-13Not applicableUs
EtomidateInjection, solution2 mg/mLIntravenousAmerican Regent, Inc.2010-06-30Not applicableUs
EtomidateInjection, solution2 mg/mLIntravenousMylan Institutional LLC2013-04-26Not applicableUs
EtomidateInjection2 mg/mLIntravenousWest Ward Pharmaceuticals Corp2016-02-25Not applicableUs
EtomidateInjection, solution2 mg/mLIntravenousSagent Pharmaceuticals2012-08-10Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
HypnomidateJanssen
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIZ22628B598
CAS number33125-97-2
WeightAverage: 244.289
Monoisotopic: 244.121177766
Chemical FormulaC14H16N2O2
InChI KeyNPUKDXXFDDZOKR-LLVKDONJSA-N
InChI
InChI=1S/C14H16N2O2/c1-3-18-14(17)13-9-15-10-16(13)11(2)12-7-5-4-6-8-12/h4-11H,3H2,1-2H3/t11-/m1/s1
IUPAC Name
ethyl 1-[(1R)-1-phenylethyl]-1H-imidazole-5-carboxylate
SMILES
CCOC(=O)C1=CN=CN1[[email protected]](C)C1=CC=CC=C1
Pharmacology
IndicationUsed in the induction of general anesthesia.
Structured Indications Not Available
PharmacodynamicsEtomidate is a non-barbiturate hypnotic that acts at the level of the reticular-activating system to produce anesthesia. Etomidate is an imidazole compound that appears to depress CNS function via GABA. Duration of action is intermediate between thiopental and methohexital, and recovery from a single dose is rapid with little residual depression. Like the barbiturates and propofol, etomidate is does not induce analgesia. Etomidate induces unconsciousness within one circulation time. Recovery is rapid as a result of extensive redistribution and rapid metabolism.
Mechanism of actionEtomidate binds at a distinct binding site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.
TargetKindPharmacological actionActionsOrganismUniProt ID
Gamma-aminobutyric acid receptor subunit alpha-1Proteinyes
agonist
HumanP14867 details
Alpha-2B adrenergic receptorProteinyes
agonist
HumanP18089 details
GABA-A receptor (anion channel)Protein groupyes
positive allosteric modulator
Humannot applicabledetails
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein binding76%, primarily to serum albumin.
Metabolism

Hepatic. Metabolized rapidly by ester hydrolysis to inactive metabolites.

Route of eliminationApproximately 75% of the administered dose is excreted in the urine during the first day after injection.
Half life75 minutes.
ClearanceNot Available
ToxicityUndesirable side effects of etomidate that may limit its use include pain on injection, myoclonus and adrenocortical suppression lasting 4-6 hours following an induction dose.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Etomidate is combined with 1,1,1,2 Tetrafluoroethane.Investigational
7-NitroindazoleThe risk or severity of adverse effects can be increased when Etomidate is combined with 7-Nitroindazole.Experimental
AcebutololEtomidate may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Aceprometazine.Approved
adipiplonThe risk or severity of adverse effects can be increased when Etomidate is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Etomidate is combined with Agomelatine.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Etomidate is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Etomidate is combined with Alfentanil.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Etomidate is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Etomidate is combined with Alprazolam.Approved, Illicit, Investigational
AlprenololEtomidate may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved, Withdrawn
AmineptineAmineptine may decrease the antihypertensive activities of Etomidate.Illicit, Withdrawn
AmisulprideThe risk or severity of adverse effects can be increased when Etomidate is combined with Amisulpride.Approved, Investigational
AmitriptylineAmitriptyline may decrease the antihypertensive activities of Etomidate.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Etomidate is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Etomidate is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Etomidate is combined with Amperozide.Experimental
Aop200704Etomidate may increase the atrioventricular blocking (AV block) activities of Aop200704.Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Etomidate is combined with Aripiprazole.Approved, Investigational
ArotinololEtomidate may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
ArticaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Etomidate is combined with Asenapine.Approved
AtenololEtomidate may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Azaperone.Vet Approved
AzelastineEtomidate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Etomidate is combined with Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Etomidate is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Etomidate is combined with Barbital.Illicit
BefunololEtomidate may increase the atrioventricular blocking (AV block) activities of Befunolol.Experimental
BenperidolThe risk or severity of adverse effects can be increased when Etomidate is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Benzocaine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Etomidate is combined with Benzyl alcohol.Approved
BetaxololEtomidate may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved
BevantololEtomidate may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
BisoprololEtomidate may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
BopindololEtomidate may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Etomidate is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Etomidate is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Etomidate.Approved
BromazepamThe risk or severity of adverse effects can be increased when Etomidate is combined with Bromazepam.Approved, Illicit
BrompheniramineThe risk or severity of adverse effects can be increased when Etomidate is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Etomidate is combined with Brotizolam.Approved, Withdrawn
BucindololEtomidate may increase the atrioventricular blocking (AV block) activities of Bucindolol.Investigational
BufuralolEtomidate may increase the atrioventricular blocking (AV block) activities of Bufuralol.Experimental, Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Bupivacaine.Approved, Investigational
BupranololEtomidate may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
BuprenorphineEtomidate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Etomidate is combined with Buspirone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Etomidate.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Etomidate is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Etomidate is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Etomidate is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Etomidate is combined with Butorphanol.Approved, Illicit, Vet Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Etomidate is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Etomidate is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Etomidate is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Etomidate is combined with Carisoprodol.Approved
CarteololEtomidate may increase the atrioventricular blocking (AV block) activities of Carteolol.Approved
CarvedilolEtomidate may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved, Investigational
CeliprololEtomidate may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved, Investigational
CetirizineThe risk or severity of adverse effects can be increased when Etomidate is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Etomidate is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Etomidate is combined with Chlordiazepoxide.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Chloroprocaine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Etomidate is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Etomidate is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Chlorzoxazone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Cinchocaine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Etomidate is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Etomidate is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Etomidate is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Etomidate is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Etomidate is combined with clomethiazole.Investigational
ClomipramineClomipramine may decrease the antihypertensive activities of Etomidate.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Etomidate is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Etomidate is combined with Clonidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Etomidate is combined with Clorazepate.Approved, Illicit
ClozapineThe risk or severity of adverse effects can be increased when Etomidate is combined with Clozapine.Approved
CocaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Etomidate is combined with Codeine.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Etomidate is combined with Cyclizine.Approved
CyclobenzaprineCyclobenzaprine may decrease the antihypertensive activities of Etomidate.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Etomidate is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Etomidate is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Etomidate is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Etomidate is combined with Dapoxetine.Investigational
deramciclaneThe risk or severity of adverse effects can be increased when Etomidate is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Etomidate is combined with Desflurane.Approved
DesipramineDesipramine may decrease the antihypertensive activities of Etomidate.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Etomidate is combined with Desloratadine.Approved, Investigational
DesvenlafaxineDesvenlafaxine may decrease the antihypertensive activities of Etomidate.Approved
DetomidineThe risk or severity of adverse effects can be increased when Etomidate is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Etomidate is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Etomidate is combined with Dexmedetomidine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Etomidate is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Etomidate is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Etomidate is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Etomidate is combined with Diazepam.Approved, Illicit, Vet Approved
DifenoxinThe risk or severity of adverse effects can be increased when Etomidate is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Etomidate is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Etomidate is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Etomidate is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Etomidate is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Etomidate is combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Etomidate is combined with Diphenoxylate.Approved, Illicit
DoramectinThe risk or severity of adverse effects can be increased when Etomidate is combined with Doramectin.Vet Approved
DosulepinDosulepin may decrease the antihypertensive activities of Etomidate.Approved
DoxepinDoxepin may decrease the antihypertensive activities of Etomidate.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Etomidate.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Etomidate is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Etomidate.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Etomidate.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Etomidate is combined with Drotebanol.Experimental, Illicit
DuloxetineDuloxetine may decrease the antihypertensive activities of Etomidate.Approved
DyclonineThe risk or severity of adverse effects can be increased when Etomidate is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Etomidate is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Etomidate is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Etomidate is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Etomidate is combined with Efavirenz.Approved, Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Etomidate.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Etomidate is combined with Entacapone.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Etomidate is combined with Escitalopram.Approved, Investigational
EsmirtazapineEsmirtazapine may decrease the antihypertensive activities of Etomidate.Investigational
EsmololEtomidate may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
EstazolamThe risk or severity of adverse effects can be increased when Etomidate is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Etomidate is combined with Eszopiclone.Approved
EthanolEtomidate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Etomidate.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Etomidate is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Etomidate is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Etomidate is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Etomidate is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Etomidate is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etomidate is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etomidate is combined with Etizolam.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etomidate is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Etomidate is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Etomidate is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Etomidate is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Etomidate is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Etomidate is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Etomidate is combined with Flibanserin.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Etomidate is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Etomidate is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Etomidate is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Etomidate is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Etomidate is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Fluphenazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Etomidate is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Etomidate is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Etomidate is combined with Fluticasone Propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Etomidate.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Etomidate is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Etomidate is combined with Fospropofol.Approved, Illicit
GabapentinThe risk or severity of adverse effects can be increased when Etomidate is combined with Gabapentin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Etomidate is combined with gabapentin enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Etomidate is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Etomidate is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Etomidate is combined with Glutethimide.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Etomidate is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Etomidate is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Etomidate is combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Etomidate is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Etomidate is combined with Heroin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Etomidate is combined with Hexobarbital.Approved
HydrocodoneEtomidate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Hydromorphone.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Etomidate.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Iloperidone.Approved
ImipramineImipramine may decrease the antihypertensive activities of Etomidate.Approved
IndalpineThe risk or severity of adverse effects can be increased when Etomidate is combined with Indalpine.Investigational, Withdrawn
IndenololEtomidate may increase the atrioventricular blocking (AV block) activities of Indenolol.Withdrawn
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Etomidate.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Etomidate is combined with Isoflurane.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Etomidate is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Etomidate is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Ketobemidone.Approved
LabetalolEtomidate may increase the atrioventricular blocking (AV block) activities of Labetalol.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Etomidate is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Etomidate is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Etomidate is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Etomidate is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Etomidate is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Etomidate is combined with Levomethadyl Acetate.Approved
LevomilnacipranLevomilnacipran may decrease the antihypertensive activities of Etomidate.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Etomidate is combined with Levorphanol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Etomidate.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Etomidate is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Etomidate is combined with Lofentanil.Illicit
LoratadineThe risk or severity of adverse effects can be increased when Etomidate is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Etomidate.Approved
LoxapineThe risk or severity of adverse effects can be increased when Etomidate is combined with Loxapine.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Etomidate is combined with Lu AA21004.Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Etomidate.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Etomidate is combined with Maprotiline.Approved
MeclizineThe risk or severity of adverse effects can be increased when Etomidate is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Etomidate is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Etomidate is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Melperone.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Etomidate is combined with Meprobamate.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Mesoridazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Etomidate is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Etomidate is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Etomidate is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Etomidate is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Etomidate is combined with Methohexital.Approved
MethotrimeprazineEtomidate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Etomidate is combined with Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Etomidate is combined with Methsuximide.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Etomidate is combined with Methylphenobarbital.Approved
MetoprololEtomidate may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved, Investigational
MetyrosineEtomidate may increase the sedative activities of Metyrosine.Approved
MianserinThe therapeutic efficacy of Etomidate can be decreased when used in combination with Mianserin.Approved
MidazolamThe risk or severity of adverse effects can be increased when Etomidate is combined with Midazolam.Approved, Illicit
MilnacipranMilnacipran may decrease the antihypertensive activities of Etomidate.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Etomidate.Approved, Investigational
MirtazapineMirtazapine may decrease the antihypertensive activities of Etomidate.Approved
MolindoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Etomidate is combined with Morphine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Etomidate.Approved, Investigational
NadololEtomidate may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Etomidate is combined with Nalbuphine.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Nefazodone.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Etomidate is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Etomidate is combined with Nitrous oxide.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Normethadone.Approved, Illicit
NortriptylineNortriptyline may decrease the antihypertensive activities of Etomidate.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Etomidate is combined with Olanzapine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Etomidate is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Etomidate is combined with Ondansetron.Approved
OpipramolOpipramol may decrease the antihypertensive activities of Etomidate.Investigational
OpiumThe risk or severity of adverse effects can be increased when Etomidate is combined with Opium.Approved, Illicit
OrphenadrineEtomidate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Etomidate is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Etomidate is combined with Oxazepam.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Oxetacaine.Investigational
OxprenololEtomidate may increase the atrioventricular blocking (AV block) activities of Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Oxymorphone.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Paliperidone.Approved
ParaldehydeEtomidate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Etomidate is combined with Paroxetine.Approved, Investigational
PenbutololEtomidate may increase the atrioventricular blocking (AV block) activities of Penbutolol.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Etomidate is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Etomidate is combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Etomidate.Approved
PerazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Etomidate is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Etomidate is combined with Pethidine.Approved
PhenobarbitalThe risk or severity of adverse effects can be increased when Etomidate is combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Etomidate is combined with Phenoxyethanol.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Etomidate is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Etomidate is combined with Pimozide.Approved
PindololEtomidate may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Etomidate is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Etomidate is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Etomidate is combined with Pomalidomide.Approved
PractololEtomidate may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
PramipexoleEtomidate may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Etomidate is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Etomidate.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Etomidate is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Prilocaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Prochlorperazine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Promethazine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Etomidate is combined with Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Propoxycaine.Approved
PropranololEtomidate may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved, Investigational
ProtriptylineProtriptyline may decrease the antihypertensive activities of Etomidate.Approved
PSD502The risk or severity of adverse effects can be increased when Etomidate is combined with PSD502.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Etomidate is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Etomidate is combined with Quetiapine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Etomidate is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Etomidate is combined with Ramelteon.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Etomidate is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Etomidate is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Etomidate.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Etomidate is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Etomidate is combined with Romifidine.Vet Approved
RopiniroleEtomidate may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Ropivacaine.Approved
RotigotineEtomidate may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Etomidate.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Etomidate is combined with S-Ethylisothiourea.Experimental
Sage 547The risk or severity of adverse effects can be increased when Etomidate is combined with Sage 547.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Etomidate is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Etomidate is combined with Secobarbital.Approved, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Etomidate is combined with Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Etomidate is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Etomidate is combined with Sevoflurane.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Etomidate.Approved
SotalolEtomidate may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
StiripentolThe risk or severity of adverse effects can be increased when Etomidate is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Etomidate is combined with Sufentanil.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Etomidate is combined with Sulpiride.Approved
SuvorexantEtomidate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Etomidate is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Etomidate.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Etomidate is combined with Tasimelteon.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Etomidate.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Etomidate is combined with Tetrodotoxin.Investigational
ThalidomideEtomidate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Etomidate is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Etomidate is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Thioridazine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Etomidate is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Etomidate is combined with Tiagabine.Approved
TianeptineTianeptine may decrease the antihypertensive activities of Etomidate.Approved
TiaprideThe risk or severity of adverse effects can be increased when Etomidate is combined with Tiapride.Investigational
TiletamineThe risk or severity of adverse effects can be increased when Etomidate is combined with Tiletamine.Vet Approved
TimololEtomidate may increase the atrioventricular blocking (AV block) activities of Timolol.Approved
TizanidineThe risk or severity of adverse effects can be increased when Etomidate is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Etomidate is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Etomidate is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Etomidate.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Etomidate is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Etomidate is combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Etomidate is combined with Triazolam.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Trifluoperazine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Triflupromazine.Approved, Vet Approved
TrimipramineTrimipramine may decrease the antihypertensive activities of Etomidate.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Etomidate is combined with Triprolidine.Approved
Uc1010The risk or severity of adverse effects can be increased when Etomidate is combined with Uc1010.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Etomidate is combined with Valproic Acid.Approved, Investigational
VenlafaxineVenlafaxine may decrease the antihypertensive activities of Etomidate.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Etomidate is combined with Vigabatrin.Approved
VortioxetineThe risk or severity of adverse effects can be increased when Etomidate is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Etomidate is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Etomidate is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Etomidate is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Etomidate.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Etomidate is combined with Zolazepam.Vet Approved
ZolpidemEtomidate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Etomidate is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Etomidate is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Etomidate is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Etomidate is combined with Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

Douglas E. Raines, “ETOMIDATE ANALOGUES THAT DO NOT INHIBIT ADRENOCORTICAL STEROID SYNTHESIS.” U.S. Patent US20130079381, issued March 28, 2013.

US20130079381
General ReferencesNot Available
External Links
ATC CodesN01AX07
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9908
Blood Brain Barrier+0.95
Caco-2 permeable+0.6275
P-glycoprotein substrateNon-substrate0.7386
P-glycoprotein inhibitor INon-inhibitor0.8567
P-glycoprotein inhibitor IINon-inhibitor0.8597
Renal organic cation transporterNon-inhibitor0.7918
CYP450 2C9 substrateNon-substrate0.7947
CYP450 2D6 substrateNon-substrate0.9117
CYP450 3A4 substrateNon-substrate0.7671
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorInhibitor0.5432
CYP450 3A4 inhibitorInhibitor0.7959
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8357
Ames testNon AMES toxic0.7989
CarcinogenicityNon-carcinogens0.8795
BiodegradationNot ready biodegradable0.5121
Rat acute toxicity2.5459 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9622
hERG inhibition (predictor II)Non-inhibitor0.8553
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Hospira inc
  • Bedford laboratories div ben venue laboratories inc
  • Parenta pharmaceuticals inc
  • Pharmaforce inc
Packagers
Dosage forms
FormRouteStrength
InjectionIntravenous2 mg/mL
Injection, solutionIntravenous2 mg/mL
Prices
Unit descriptionCostUnit
Amidate 2 mg/ml vial1.55USD ml
Amidate 2 mg/ml ampul1.19USD ml
Etomidate 2 mg/ml vial1.18USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point142-142.8Godefroi, E.F. and Van Der Eijcken, C.A.M.; U.S. Patent 3,354,173; November 21, 1967; assigned to Janssen Pharrnaceutica NV (Belgium).
water solubility63.2 mg/LNot Available
logP3.05POMONA (1987)
Predicted Properties
PropertyValueSource
Water Solubility0.477 mg/mLALOGPS
logP2.66ALOGPS
logP2.5ChemAxon
logS-2.7ALOGPS
pKa (Strongest Basic)4.54ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area44.12 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity69.59 m3·mol-1ChemAxon
Polarizability26.43 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as n-substituted imidazoles. These are heterocyclic compounds containing an imidazole ring substituted at position 1.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassAzoles
Sub ClassImidazoles
Direct ParentN-substituted imidazoles
Alternative Parents
Substituents
  • Benzenoid
  • N-substituted imidazole
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Carboxylic acid ester
  • Azacycle
  • Monocarboxylic acid or derivatives
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Martin LJ, Oh GH, Orser BA: Etomidate targets alpha5 gamma-aminobutyric acid subtype A receptors to regulate synaptic plasticity and memory blockade. Anesthesiology. 2009 Nov;111(5):1025-35. doi: 10.1097/ALN.0b013e3181bbc961. [PubMed:19809285 ]
  4. Desai R, Ruesch D, Forman SA: Gamma-amino butyric acid type A receptor mutations at beta2N265 alter etomidate efficacy while preserving basal and agonist-dependent activity. Anesthesiology. 2009 Oct;111(4):774-84. doi: 10.1097/ALN.0b013e3181b55fae. [PubMed:19741491 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Epinephrine binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phent...
Gene Name:
ADRA2B
Uniprot ID:
P18089
Molecular Weight:
49565.8 Da
References
  1. Creagh O, Torres H, Rodriguez N, Gatica SR: Alpha-2B adrenergic receptor mediated hemodynamic profile of etomidate. P R Health Sci J. 2010 Jun;29(2):91-5. [PubMed:20496522 ]
  2. Paris A, Philipp M, Tonner PH, Steinfath M, Lohse M, Scholz J, Hein L: Activation of alpha 2B-adrenoceptors mediates the cardiovascular effects of etomidate. Anesthesiology. 2003 Oct;99(4):889-95. [PubMed:14508322 ]
Kind
Protein group
Organism
Human
Pharmacological action
yes
Actions
positive allosteric modulator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).
Components:
NameUniProt IDDetails
Gamma-aminobutyric acid receptor subunit alpha-1P14867 Details
Gamma-aminobutyric acid receptor subunit alpha-2P47869 Details
Gamma-aminobutyric acid receptor subunit alpha-3P34903 Details
Gamma-aminobutyric acid receptor subunit alpha-4P48169 Details
Gamma-aminobutyric acid receptor subunit alpha-5P31644 Details
Gamma-aminobutyric acid receptor subunit alpha-6Q16445 Details
Gamma-aminobutyric acid receptor subunit beta-1P18505 Details
Gamma-aminobutyric acid receptor subunit beta-2P47870 Details
Gamma-aminobutyric acid receptor subunit beta-3P28472 Details
Gamma-aminobutyric acid receptor subunit deltaO14764 Details
Gamma-aminobutyric acid receptor subunit epsilonP78334 Details
Gamma-aminobutyric acid receptor subunit gamma-1Q8N1C3 Details
Gamma-aminobutyric acid receptor subunit gamma-2P18507 Details
Gamma-aminobutyric acid receptor subunit gamma-3Q99928 Details
Gamma-aminobutyric acid receptor subunit piO00591 Details
Gamma-aminobutyric acid receptor subunit thetaQ9UN88 Details
References
  1. ChEMBL Compound Report Card [Link]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid 11-beta-monooxygenase activity
Specific Function:
Has steroid 11-beta-hydroxylase activity. In addition to this activity, the 18 or 19-hydroxylation of steroids and the aromatization of androstendione to estrone have also been ascribed to cytochrome P450 XIB.
Gene Name:
CYP11B1
Uniprot ID:
P15538
Molecular Weight:
57572.44 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid 11-beta-monooxygenase activity
Specific Function:
Preferentially catalyzes the conversion of 11-deoxycorticosterone to aldosterone via corticosterone and 18-hydroxycorticosterone.
Gene Name:
CYP11B2
Uniprot ID:
P19099
Molecular Weight:
57559.62 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxygen binding
Specific Function:
Catalyzes the formation of aromatic C18 estrogens from C19 androgens.
Gene Name:
CYP19A1
Uniprot ID:
P11511
Molecular Weight:
57882.48 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic transporter activity
Specific Function:
Facilitative glucose transporter. This isoform may be responsible for constitutive or basal glucose uptake. Has a very broad substrate specificity; can transport a wide range of aldoses including both pentoses and hexoses.
Gene Name:
SLC2A1
Uniprot ID:
P11166
Molecular Weight:
54083.325 Da
References
  1. Stephenson KN, Croxen RL, El-Barbary A, Fenstermacher JD, Haspel HC: Inhibition of glucose transport and direct interactions with type 1 facilitative glucose transporter (GLUT-1) by etomidate, ketamine, and propofol: a comparison with barbiturates. Biochem Pharmacol. 2000 Sep 1;60(5):651-9. [PubMed:10927023 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23